We All Want Life to Return to Normal, But Widespread Testing is a Problem
With a Severe Need, Undervalued Relay Medical (CSE:RELA)(OTC:RYMDF) Could Scale Up Widespread Rapid Testing and Get Us Back to Normal
Most of us are tired of this situation we’re in.
We’re exhausted from the lockdowns, and over social distancing. We have to wear these masks everywhere and don’t feel safe returning to work, schools, sports, or even the movies.
It’s interfering with the economy, social and mental health, and our daily lives.
At this point, all we want to do is resume some sort of normalcy.
Vaccines were supposed to get us there, however, the widespread roll-out process has been a mess thus far. To call it clunky is an understatement. The world is also unclear how effective they will be, and there appears to be some serious public trust issues.
For the time being, it does not appear that the “old normal” will return anytime soon without widespread testing to make sure we’re all healthy.
Unfortunately, there appears to be key problems with testing
For one, according to Reuters, demand for testing devices could outstrip supply for a long time, as noted by Roche Chief Executive Severin Schwan.(1)
Additionally, according to CNBC, labs nationwide appear to be struggling to get their hands on sufficient supply. The network further added that “the surge in demand is yet again stressing the supply chain.” (2)
Plus, not all current solutions seem to be created equal.(3)
- Lab-based centralized testing is simply not scalable. There are not enough testing locations, there is limited testing capacity, and it can take days to receive results. It can also be quite costly.(3)
- Some of the approved rapid tests have claimed to have unconfirmed distribution timelines. There also appears to be insufficient quantities for mass deployment.(3)
Granted, there are Rapid Diagnostic Tests (RDTs) that can be ideal for testing. But they are far from the perfect solution.(3)
This is where Relay Medical and Fionet can come into play and potentially solve many of those issues.
Relay Medical not only appears to offer rapid widespread testing administration with real-time geo-tagged data but also seemingly does so while greatly reducing testing errors.(3)
Additionally, with the existing challenges of scaling lab-based testing, Relay Medical’s Fionet platform appears to make it possible to dramatically scale up rapid testing into community-based settings (workplaces, airports, schools, etc). This could potentially facilitate a safe return to daily life. Through accurate, widespread, and proactive screening/surveillance testing, rather than reactive testing, the outlook for Relay Medical and Fionet appears to be positive.
After finding triple bottom support in early Dec. 2020 at around 18 cents, the stock recovered to a recent high of about 35 cents. The stock, for now, appears to have pulled back to around 28 cents a share. However, with testing needs still in full force, the stock could potentially recover and see higher highs.
Most of the stock’s short-, medium-, and long-term indicators all appear to be positive as well, including its 20 Day Moving Average, 20 – 50 Day MACD Oscillator, 20 – 100 Day MACD Oscillator, 20 – 200 Day MACD Oscillator, 50 Day Moving Average, 50 – 100 Day MACD Oscillator, 50 – 150 Day MACD Oscillator, 50 – 200 Day MACD Oscillator, 100 Day Moving Average, 150 Day Moving Average, 200 Day Moving Average, and 100 – 200 Day MACD Oscillator.
Additionally, between late Dec. 2020 and Jan. 2021, the stock appears to have seen its volume spike. On Dec. 21, for example, volume spiked to approximately 12.77 million shares. On Dec. 31, it spiked to approximately 2.84 million shares. On Jan. 6, it spiked to about 1.12 million shares. The daily average volume is typically about 292,925, so thee spikes appear to be significant.(4)
Relay Medical Corp. is a medical technology company that specializes in point-of-care diagnostics and artificial intelligence. The company claims to have a portfolio of technology and IP assets in various stages of development and commercialization.
With the current health situation our world is in right now, Relay Medical’s Fionet platform appears to have found a lane to potentially solve the problem of scalable lab-based testing. With the current situation only getting worse, demand for testing devices could overwhelm supply for a long time. There is simply not a sufficient enough supply chain to not only build the testing infrastructure, but not enough of a supply chain to test both quickly and accurately. It is simply too expensive, there are not enough testing locations, there is limited testing capacity, and it can take days to receive results.
With Fionet’s platform, it not only appears to be accurate but also appears to be widespread, quick, and efficient. The Fionet platform claims to have the ability to do high-throughput testing (60/tests per hour) per device- significantly more than competitors.
With its speed and universal compatibility with any RDT – antigen, antibody, and any condition- Fionet could be well positioned to help solve testing needs for major industries like: airports, long term care homes, cruise ships, schools, sports & events, theme parks, and more.
This does not appear to be any run of the mill experimental solution either. Fionet appears to have already had long-term success with Ebola, Malaria, HIV, and other situations, with over around one million patients in 12 countries. (Source 3) The company also claims to have already worked with world-class organizations like USAID, WHO, CDC and Bill & Melinda Gates.
Fionet, through a mobile device and the cloud, could make its ambitions a reality in bringing us back to normal. Its mobile device, first and foremost, appears to make it easier to run high-quality rapid testing programs at massive scale, and in community settings. The Fionet platform could potentially help facilitate a safe return to everyday life with rapid, widespread testing administration, real-time, geo-tagged data to inform decisions, and accurate results.
This platform lease/service appears to be billed monthly re-occurring over a 1-3 year term. However, because it is seemingly so accurate, error reduction and what looks to be a low monthly price could result in net-saving for customers. Less errors = less retesting.
Because the device is fully integrated with the cloud, it appears to report real-time results, insights and actionable intelligence of frontline activity to healthcare supervisors
Over the last few months, the company appears to have seen significant developments.
- In October 2020, Relay and Fio Corporation — together Fionet Rapid Response Group — announced that its Fionet response devices could be produced by US-based, FDA-approved, high-volume contract manufacturer, KeyTronic. KeyTronic appears to now be creating a Fionet device assembly line.(3)
- In November 2020, Fionet announced over CAD$500,000 in contracts for the Fionet Mobile testing and tracking platform.(3)
- Fionet reported an agreement with King Heights Academy and Paramount Ice in Toronto to bring the Fionet mobile testing and tracking platform to their facilities for pilot deployments.(3)
- By late November 2020, Fionet signed an MOU with Lonestar Life Sciences to bring rapid diagnostic testing to rural hospitals in Texas.(3)
- In December 2020, Fionet announced a sales agreement with the U.S. Government, through the U.S. Agency for International Development (USAID), to deploy Fionet devices to over around 100 community-based healthcare sites in Africa.(3)
The companies also announced multiple lateral flow rapid diagnostic tests that are expected to operate directly with the Fionet platform:(3)
- Abbott Panbio CV Ag Rapid Test. The test appears to be CE marked and seems to be approved by Health Canada for point of care diagnosis. This test also claims to be used across Europe and Africa. Recently, the Government of Canada claimed to have acquired around 20 million tests to be used by public health authorities.
- Roche CV Rapid Antigen Test. The test appears to be CE marked for markets accepting the designation including the European Union. Roche previously claimed that it would be able to produce up to 100 million tests per month for worldwide distribution.
- Proprietary Innovation Labs Antibody and Antigen Tests. Relay Medical recently announced the signing of an LOI for the exclusive sales and distribution rights of these tests. Both tests appear to be CE marked with a potential production capacity of 25 million per month.
With these tests on hand, development activities could commence configuring the Fionet software and analysis engine to be compatible with identifying, error checking, and interpreting results. Onboarding of the tests could potentially support trial or pilot deployments for upcoming clients.
Yoav Raiter — CEO
20+ years of experience leading the development of large-scale software teams, with 5+ years in medical device development management.
Clark Kent — President
Capital markets professional with extensive experience leading corp. development and finance.
Tom Glawdel — Chief Science Officer
PhD in Mechanical and Mechatronics Engineering with experience in the development of microfluidic, molecular diagnostics and medical devices.
iGAL Roytblat – Chief Technical Officer
25 years’ experience in the technology sector, formerly overseeing software and hardware development at Kangaroo.
Paul Glavina – VP, In Vitro Diagnostics
Paul spent over 25 years with Abbott Point of Care and its precursor, i-STAT Corporation, designing, developing, manufacturing, and marketing the world’s first handheld blood gas and electrolyte analyzer. He is an inventor with a number of patents and an Abbott Chairman’s Award.
Chris Hopkins — Chief Financial Officer
25 years of financial management experience in the capital markets, spent mostly in senior roles with public mining companies, including U.S. Silver, Rio Algo, BHP Billiton and Suncor.
Robert Carducci — CCO, Glow LifeTech Corp.
Robert is a marketing leader with a passion for growing brands. He has 10+ years of CPG and tech start-up marketing experience including senior roles leading global brands at Nestle Canada and most recently at green leaf tech platform Leafly.
Medhanie Tekeste — Director
20+ years of information systems experience including many years of broad-based management expertise in systems development, implementation and support. Currently, he is the Chief Information Officer at Apotex Inc.
Sid Thomas — Director
Successful business leader with executive senior management expertise in software development, software project management and sales development. Significant leader in the growth of DMC Inc, until its sale in 2000. In 2003 founded VERAX Solutions Inc. a software development co. and was instrumental in its substantial growth until its successful sale in 2017.
Michael Minder – Director
Finance professional with 15+ years of international banking experience. He held senior leadership roles in Asset and Wealth Management for Credit Suisse Group in both Switzerland and North America, managing assets of high net worth accounts. In 1998 he left the Credit Suisse Group to form his own firm.
Gerard Edwards — Chairman
30 years of independent business experience as a serial entrepreneur and venture capitalist. He has developed companies in the technology sector, oil & gas exploration/development, and real estate development.
Greg Van Staveren — Director
Currently President of Strategic Financial Services, he has acted as CFO, COO or as a member of BOD for many private and public companies and has been a key part of management for several very successful high growth companies. Until 1998, he was a Partner at KPMG.
Colin Greenway — Strategic Advisor
Mr. Colin Greenaway has 37 years of policing experience, and currently occupies a senior leadership role with one of Canada’s largest policing agencies. Colin has advised and contributed to companies in the medical field; specifically, an innovative concussion clinic and an artificial intelligence-based genomics company.
Dr. Tejal Patel — Advisor
Clinical associate prof. at the Univ. of Waterloo with research interests in pharmacotherapeutic management of neurological conditions, (dementia, epilepsy and Parkinson’s disease). Her current focus is on the assessment, classification and management of drug related problems in persons presenting with cognitive impairment & elderly in primary care.
Barak Carmon — Advisor
Mr. Carmon co-founded and served in executive technical, operational, financial and business development positions in four companies. Currently he is the Managing director of JBCI Holdings, an advisory firm which specializes in fundraising, business development and strategic planning, in addition to serving and investing in tech companies and select venture funds.
Chris Malkhassian — Advisor
Mr. Malkhassian joins Relay Medical from A&D Precision Ltd., where he served as Corporate Counsel, managing legal, commercial, corporate, and risk. Prior to A&D, he practiced corporate law at ML Lawyers; Teplitsky, Colson; and Greenspan, White. Chris sits on the Toronto Jr. Canadiens Advisory Board bringing 25+ years of experience with various hockey organizations. Chris completed his undergrad at York University and obtained his law degree from the University of Windsor.
Dr. Murray Berall — Advisor
Dr. Berall is a Nephrologist and Sleep Medicine Specialist at the Vaughn Heart Institute and at the Humber River Hospital. He studied genetics at McGill University and attended medical school at Dalhousie University. He completed his postgraduate education in Internal and Nephrology at the University of Toronto. He was the first Director of Dialysis at HRH and helped oversee the creation of the initial program.
Source 2: https://www.cnbc.com/2020/11/18/covid-testing-faces-delays-again-as-demand-spikes-ahead-of-the-holidays-.html
Source 3: https://www.relaymedical.com
Source 4: https://ca.finance.yahoo.com/quote/RELA.CN/history?p=RELA.CN
This website / media webpage is owned, operated and edited by TD Media LLC. Any wording found on this website / media webpage or disclaimer referencing to “I” or “we” or “our” or “TD Media” refers to TD Media LLC. This website / media webpage is a paid advertisement, not a recommendation nor an offer to buy or sell securities. Our business model is to be financially compensated to market and promote small public companies. By reading our website / media webpage you agree to the terms of our disclaimer, which are subject to change at any time. We are not registered or licensed in any jurisdiction whatsoever to provide investing advice or anything of an advisory or consultancy nature and are therefore are unqualified to give investment recommendations. Always do your own research and consult with a licensed investment professional before investing. This communication is never to be used as the basis for making investment decisions and is for entertainment purposes only. At most, this communication should serve only as a starting point to do your own research and consult with a licensed professional regarding the companies profiled and discussed. Conduct your own research. Companies with low price per share are speculative and carry a high degree of risk, so only invest what you can afford to lose. By using our service you agree not to hold our site, its editor’s, owners, or staff liable for any damages, financial or otherwise, that may occur due to any action you may take based on the information contained within our website / media webpage.We do not advise any reader take any specific action. Losses can be larger than expected if the company experiences any problems with liquidity or wide spreads. Our website / media webpage are for entertainment purposes only. Never invest purely based on our alerts. Gains mentioned in our website / media webpage may be based on end-of-day or intraday data. This publication and their owners and affiliates may hold positions in the securities mentioned in our alerts, which we may sell at any time without notice to our subscribers, which may have a negative impact on share prices. If we own any shares we will list the information relevant to the stock and number of shares here. TD Media business model is to receive financial compensation to promote public companies. To conduct investor relations advertising, marketing and publicly disseminate information not limited to our Websites, Email, SMS, Push Notifications, Influencers, Social Media Postings, Ticker Tags, Press Releases, Online Interviews, Podcasts, Videos, Audio Ads, Banner Ads, Native Ads, Responsive Ads. This compensation is a major conflict of interest in our ability to be unbiased regarding. Therefore, this communication should be viewed as a commercial advertisement only. We have not investigated the background of the hiring third party or parties. The third party, profiled company, or their affiliates likely wish to liquidate shares of the profiled company at or near the time you receive this communication, which has the potential to hurt share prices. Any non-compensated alerts are purely for the purpose of expanding our database for the benefit of our future financially compensated investor relations efforts. Frequently companies profiled in our alerts may experience a large increase in volume and share price during the course of investor relations marketing, which may end as soon as the investor relations marketing ceases. Our emails may contain forward-looking statements, which are not guaranteed to materialize due to a variety of factors We do not guarantee the timeliness, accuracy, or completeness of the information on our website / media webpage. The information in our website / media webpage is believed to be accurate and correct, but has not been independently verified and is not guaranteed to be correct. The information is collected from public sources, such as the profiled company’s website and press releases, but is not researched or verified in any way whatsoever to ensure the publicly available information is correct. Furthermore, TD Media often employs independent contractor writers who may make errors when researching information and preparing these communications regarding profiled companies. Independent writers’ works are double-checked and verified before publication, but it is certainly possible for errors or omissions to take place during editing of independent contractor writer’s communications regarding the profiled company(s). You should assume all information in all of our communications is incorrect until you personally verify the information, and again are encouraged to never invest based on the information contained in our written communications. The information in our disclaimers is subject to change at any time without notice.
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 01/13/2021 and ending on 02/11/2021 to publicly disseminate information about (RYMDF:US) (RELA:CA) via digital communications. We have been paid one hundred thousand dollars USD. We own zero shares of (RYMDF:US) (RELA:CA)
Pursuant to an agreement between TD Media LLC and Winning Media LLC, TD Media LLC has been hired for a period beginning on 02/12/2021 and ending on 03/15/2021 to publicly disseminate information about (RYMDF:US) (RELA:CA) via digital communications. We have been paid an additional one hundred thousand dollars USD. To date we have been paid two hundred thousand dollars USD to disseminate information about (RYMDF:US) (RELA:CA) via digital communications. We own zero shares of (RYMDF:US) (RELA:CA).
(Last updated: 12-11-2023 4:49:05)
65 International Blvd.
Etobicoke, ONT M9W 6L9
Relay Medical is an integrated accelerator platform, developing a portfolio of medical technologies for pre-commercial exits in the Healthtech marketplace.